Biocryst Pharmaceuticals buy Royal Bank of Canada
Start price
30.06.25
/
50%
€7.60
Target price
30.06.26
€11.09
Performance (%)
-20.15%
Price
17.12.25
€6.07
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -20.15%. This prediction currently runs until 30.06.26. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biocryst Pharmaceuticals | -7.413% | -7.413% |
| iShares Core DAX® | -1.212% | 1.925% |
| iShares Nasdaq 100 | -4.714% | -1.810% |
| iShares Nikkei 225® | -2.976% | -2.660% |
| iShares S&P 500 | -2.744% | -0.448% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "outperform" rating re-affirmed by analysts at Royal Bank Of Canada. They now have a $13.00 price target on the stock.
Ratings data for BCRX provided by MarketBeat
Stopped prediction by Royal_Bank_of_Canada for Biocryst Pharmaceuticals
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€8.90
06.05.25
06.05.25
€11.51
06.05.26
06.05.26
-31.78%
17.12.25
17.12.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€5.91
11.04.25
11.04.25
€9.75
11.04.26
11.04.26
2.71%
17.12.25
17.12.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€7.79
25.02.25
25.02.25
€10.47
25.02.26
25.02.26
-22.06%
17.12.25
17.12.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.61
05.11.24
05.11.24
€9.16
05.11.25
05.11.25
-6.99%
06.11.25
06.11.25
Biocryst Pharmaceuticals
Start price
Target price
Perf. (%)
€6.95
25.09.23
25.09.23
€9.44
25.09.24
25.09.24
-2.42%
26.09.24
26.09.24